#Coronavirus Disease Research #References (AMEDEO, June 27 '26)

 

Antiviral Res

1. WANG W, Wang S, Meng X, Zhao Y, et al
   Corrigendum to "A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" [Antivir. Res. 225 (2024) 105854].
   Antiviral Res. 2026 Jun 22:106465. doi: 10.1016/j.antiviral.2026.106465.
   PubMed        
   
   
2. ZHANG G, Deng F, Luo Y, Chen J, et al
   ITGA4 drives pathogenesis of flavivirus and inhibition of it protects mice against Japanese encephalitis virus infection.
   Antiviral Res. 2026;252:106471.
   PubMed         Abstract available
   
   

   
   BMJ

3. BONVOISIN T, Todsen AL, Perinpanathan T
   Deeper understanding of healthcare system "overwhelm" during covid-19 is essential for coherent pandemic strategy.
   BMJ. 2026;393:e100006.
   PubMed        
   
   

   
   Int J Infect Dis

4. ZHANG H, Xiang C, Mu Y, Gu X, et al
   Association of acute-phase corticosteroid use with SARS-CoV-2 reinfection among hospitalized COVID-19 survivors:a 3-year follow-up study.
   Int J Infect Dis. 2026 Jun 19:108903. doi: 10.1016/j.ijid.2026.108903.
   PubMed         Abstract available
   
   
5. VAN WEELDEN G, Rabie H, Redfern A, Barday MA, et al
   Evaluating Mucosal and Systemic Immunity in an Observational Cohort of South African Children Hospitalised with Acute Respiratory Tract Infections.
   Int J Infect Dis. 2026 Jun 20:108902. doi: 10.1016/j.ijid.2026.108902.
   PubMed         Abstract available
   
   
6. VAN BILSEN CJA, Wijnen SMCE, Pagen DME, Hoebe CJPA, et al
   Workforce exit and work productivity loss in adults with and without post-COVID-19 condition: the PRIME post-COVID cohort study.
   Int J Infect Dis. 2026 Jun 23:108913. doi: 10.1016/j.ijid.2026.108913.
   PubMed         Abstract available
   
   
7. JUBAIR M, Begum MN, Samia NSN, Alam MS, et al
   Epidemiological and Genomic Surveillance of Influenza virus A, RSV B and SARS-CoV-2 in Bangladesh (2022-2024).
   Int J Infect Dis. 2026 Jun 24:108910. doi: 10.1016/j.ijid.2026.108910.
   PubMed         Abstract available
   
   
8. ENA N, Garcia-Abellan J, Ledesma C, Fernandez-Gonzalez M, et al
   Low prevalence of bacterial coinfection at hospital admission in COVID-19 and the role of procalcitonin as a rule-out biomarker (Revised Version).
   Int J Infect Dis. 2026 Jun 25:108925. doi: 10.1016/j.ijid.2026.108925.
   PubMed         Abstract available
   
   
9. QUEK AML, Ooi DSQ, Teng O, Foon CH, et al
   Adiposity shapes the immune architecture independent of antibody responses in mild SARS-CoV-2 Infection.
   Int J Infect Dis. 2026 Jun 26:108932. doi: 10.1016/j.ijid.2026.108932.
   PubMed         Abstract available
   
   
10. WAKAMATSU K, Tananari Y, Nakamura K, Nakamura T, et al
    Oropharyngeal swabs show higher bacterial loads than nasopharyngeal swabs for PCR detection of pertussis: a multicenter prospective study.
    Int J Infect Dis. 2026 Jun 26:108937. doi: 10.1016/j.ijid.2026.108937.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. HELAL A, Aljehani ND, Ghazwani A, Alsulaiman RM, et al
    Broadly Protective Antibody-Like Vaccines Against Highly Pathogenic Coronaviruses.
    J Med Virol. 2026;98:e71008.
    PubMed         Abstract available
    
    
12. SILVA RMD, Soper MS, Neves JH, Maciel CEA, et al
    Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID-19 Patients Treated With Tocilizumab.
    J Med Virol. 2026;98:e71028.
    PubMed         Abstract available
    
    
13. FOURIE E, van Leeuwen LM, Euser SM, Wildenbeest JG, et al
    Long-Term Dynamics of Pediatric Respiratory Pathogens Before, During, and After the COVID-19 Pandemic: Evidence From Nine Years of Surveillance in the Netherlands (2015-2023).
    J Med Virol. 2026;98:e71022.
    PubMed         Abstract available
    
    
14. MOHI UD DIN MALIK M, Saraf A, Bhrushundi MP
    Comment on "Prevalence and Risk Factors for Persistent Post-COVID-19 Condition at 3, 6, 12, and 18 Months After Initial Infection Among Adults Living in a Community of Japan: Yao COVID-19 Study".
    J Med Virol. 2026;98:e71041.
    PubMed        
    
    
15. NABEYA D, Kinjo T, Nishiyama N, Kami W, et al
    Virus-Specific Impact of Respiratory Viruses on Adult Emergency Department Outcomes.
    J Med Virol. 2026;98:e71039.
    PubMed         Abstract available
    
    

    
    J Virol

16. BERMEJO-JAMBRINA M, Pauzuolis M, Kimpel J, Gerold G, et al
    Double trouble: how co- and superinfections shape viral dynamics and host responses.
    J Virol. 2026 Jun 23:e0205525. doi: 10.1128/jvi.02055.
    PubMed         Abstract available
    
    

    
    N Engl J Med

17. RUELLA M, Paruzzo L, Chong ER, Chong EA, et al
    Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
    N Engl J Med. 2026;394:2440-2448.
    PubMed         Abstract available
    
    

    
    Nature

18. LOCCI M, Pardi N
    Immunological mechanisms of mRNA vaccines for infectious diseases.
    Nature. 2026;654:892-901.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

19. SHU HJ, Chang ST, Gameiro RR, Gichoya JW, et al
    Impact of Exposure Parameters on Deep Learning Models in Chest Radiography and Implications for Deployment.
    Radiol Artif Intell. 2026 Jun 24:e250731. doi: 10.1148/ryai.250731.
    PubMed         Abstract available